Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Capecitabine in First-Line Gastric Cancer
NCT00526669Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in gastric cancer (GC), sponsored by GSK. Primary endpoints: Change From Start of Run-in Period in Biomarker Expression Levels at Day 7, Response Rate up to 85 weeks and 1 more. Started Mar 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00526669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526669.